Drug Trial News

RSS

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Medicago Inc. a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today reported positive interim results from a Phase I human clinical trial with its H5N1 Avian Influenza vaccine candidate ("H5N1 vaccine"). The vaccine was found to be safe, well tolerated and also induced a solid immune response.

21 Dec 2009

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has initiated a Phase 1/2 clinical trial evaluating SGX201, a time-release formulation of oral beclomethasone 17,21-dipropionate (oral BDP), for the prevention of acute radiation enteritis.

21 Dec 2009

Preliminary results from Phase III study of afamelanotide in EPP announced

Clinuvel Pharmaceuticals Limited today announced that it has obtained promising 4-months results in testing afamelanotide in a multicentre randomised double-blind placebo controlled Phase III study in EPP (CUV017).

21 Dec 2009

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

Taro Pharmaceutical Industries Ltd. announced that it has begun Phase I clinical trials in Canada with T2007, the second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.

18 Dec 2009

U.S. health officials announce shift in focus of prep trial in Botswana

U.S. health officials on Thursday announced they will shift the focus of a clinical trial in Botswana aimed at testing pre-exposure prophylaxis (PrEP) - the strategy that "a daily low dose of the drugs, which interfere with the ability of the virus to replicate, could also lower the risk of infection" - after researchers discovered they would be unable to determine the efficacy of Truvada, the medicine used in the trial, Reuters reports.

18 Dec 2009

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

PolyMedix, Inc., an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders, has successfully completed the first two segments of a Phase 1B clinical safety study with its novel antibiotic drug candidate PMX-30063.

18 Dec 2009

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Flamel Technologies today announced the initiation of a Phase 2a clinical trial of Flamel’s Interferon alpha-2b XL (IFN-alpha-2b XL), which is based on Flamel’s Medusa® platform for controlled release of biologics. IFN-alpha-2b XL is being developed as a controlled release of unmodified interferon alpha-2b for the treatment of chronic hepatitis C virus (HCV).

18 Dec 2009

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Celgene Corporation today announced the National Cancer Institute (NCI), a part of the National Institutes of Health, reported initial data from a Phase III, randomized, double-blind, multi-center clinical study led by the Cancer and Leukemia Group B (CALGB).

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

Amarillo Biosciences, Inc. (ABI) today announced that its ongoing study of oral interferon as prevention/treatment of influenza and other respiratory illnesses in Perth, Australia is nearing completion.

17 Dec 2009

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain

DURECT Corporation announced today positive results from a 60 patient Phase IIb clinical trial of POSIDUR(TM), a proprietary product under development for the treatment of post-surgical pain.

17 Dec 2009

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company creating a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that effective immediately, its partner, Alcon Inc. has increased its on-going financial support of the company's research and development efforts by more than $2 million per year. The additional funding is expected to enhance NovaBay's pre-clinical and clinical development programs in the areas of eye, ear and sinus infections, as well as contact lens solutions.

17 Dec 2009

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients.

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium.

17 Dec 2009

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Ipsen, an innovation-driven global specialty pharmaceutical group, today announced that its partner Roche has disclosed headline results of the fourth and fifth of eight T-emerge phase III studies in patients with diabetes for taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence.

17 Dec 2009

Drug Trial News

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Positive interim results from Medicago's H5N1 vaccine Phase I human clinical trial

Soligenix commences SGX201 Phase 1/2 clinical trial for acute radiation enteritis prevention

Preliminary results from Phase III study of afamelanotide in EPP announced

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

U.S. health officials announce shift in focus of prep trial in Botswana

PolyMedix completes first two segments of its PMX-30063 antibiotic drug candidate Phase 1B study

Flamel Technologies initiates IFN-alpha-2b XL Phase 2a clinical trial for HCV

Initial data from REVLIMID Phase III trial in multiple myeloma patients announced

Phase 2 clinical study of STA-9090 in NSCLC initiated

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Update on Phase 2 clinical trial of oral interferon announced by Amarillo Biosciences

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Positive results from DURECT's Phase IIb POSIDUR clinical trial for post-surgical pain

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Anadys Pharmaceuticals reports positive 4-week results from its ANA598 Phase II study for HCV

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

Sanofi Pasteur uses PHT’s LogPad System and StudyWorks online portal for its Phase II trial

Roche discloses results of two of eight taspoglutide T-emerge phase III studies in diabetes patients

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

Latest News